Morgan Stanley Lowered the Firm's PT on Merck & Co (MRK), Kept a Hold Rating

Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $99 to $98, while keeping a Hold rating on the stock.

This small reduction reflects a cautious outlook amid broader challenges facing large pharma companies this year. Flynn highlighted that the company, like its peers, has underperformed due to the challenging macroeconomic environment. He pointed out that ongoing policy uncertainties, including drug pricing reforms, tariffs, transfer pricing issues, and changes in FDA staffing, are adding complexity to the business climate.

Merck & Co., Inc. (NYSE:MRK) faced a 2% decrease in total worldwide sales during the fiscal first quarter of 2025. The company expects full-year sales to be between $64.1 billion and $65.6 billion.

Merck & Co., Inc. (NYSE:MRK) is a healthcare company that develops and sells prescription medicines, vaccines, and animal health products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.